Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Down 56.6% in July

Gain Therapeutics, Inc. (NASDAQ:GANX) saw a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 83,800 shares, a drop of 56.6% from the June 30th total of 193,000 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average trading volume of 275,000 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on GANX. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Gain Therapeutics in a research note on Tuesday, April 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Thursday, July 11th.

Gain Therapeutics Price Performance

Shares of GANX stock traded up $0.05 during trading hours on Friday, hitting $1.09. 50,827 shares of the company’s stock were exchanged, compared to its average volume of 210,485. The company has a market capitalization of $19.67 million, a PE ratio of -0.73 and a beta of 0.35. Gain Therapeutics has a 12-month low of $1.02 and a 12-month high of $5.33. The business’s 50 day simple moving average is $1.69 and its 200-day simple moving average is $3.06. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. On average, equities research analysts anticipate that Gain Therapeutics will post -1.03 earnings per share for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.